International Society for antiviral research

Abstract Submission

Abstract Details 

We welcome short oral presentations and posters describing the activity of well-defined chemical compounds for the treatment of viral diseases of humans and vertebrate animals and on the protective activity of vaccines for humans.  Reports of the antiviral effect of a novel small-molecule drug are encouraged to include chemical structures, as long as such reporting does not negatively impact the potential development of novel antivirals.  Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis.  We discourage the submission of abstracts reporting the antiviral activity of unpurified natural products, or of partially purified substances.  Abstracts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will be rejected.  Presentations on antiseptics with broad-spectrum antimicrobial activity will not be considered.  We also discourage talks or posters on silicodocking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays.

Submission tracks for ICAR2023 are:

• Acute GI Viruses
  
• Arboviruses
• Broad Spectrum Antiviral Drugs, Biothreat Viruses, and Pandemic Preparedness
• Chronic Hepatitis Viruses
• Coronaviruses, Influenza, RSV, and Other Respiratory Viruses
• Herpesviruses, Adenoviruses, Papillomaviruses
• HIV and Other Retroviruses

Presentation Formats

• Short Oral Presentations - Authors who elect to be considered for an oral presentation must plan to present onsite in Lyon.  Should your abstract be selected for an oral presentation, you will be requested to confirm your in-person presentation plans no later than January 16, 2023.  
  


• Poster Presentations - Authors have the option to present in a poster session onsite in Lyon or present a virtual-only poster.  If you are attending the conference in Lyon, it is expected that you will present your poster in-person and upload a virtual poster.  Upon receiving your abstract acceptance notification, you will be requested to confirm your attendance plans (onsite or virtual) no later than January 16, 2023.  All accepted poster presenters (onsite and virtual) will be required to submit their virtual posters no later than February 20, 2023.  

What is the difference between a virtual poster and onsite poster?

About the ICAR2023 Program

In-person and virtual programming options will be available for ICAR2023 .  The onsite meeting in Lyon will include oral and poster sessions, plenary talks, ISAR awardee lectures and several special sessions and networking events.  The oral sessions will be recorded and available to all registered attendees on the virtual platform for on-demand viewing.  All accepted posters will be available via the virtual platform with online Q&A chat boards to promote discussion. All on-demand content will be available through April 17, 2023.  

1. Login to the submission site to start your abstract submission. 
2. When asked if you would like to be considered for a Poster Award, select "Yes”. 
   
3. Answer the subsequent questions. 
4. Further details will be provided after abstract acceptance notifications have been sent. Please note that you will be required to submit an electronic poster by February 20, 2023. 
   
5. Anyone who is selected for an oral presentation, but would like to also compete for a Poster Award, should notify ICAR Staff and prepare a poster to present at the meeting.